DexCom, Inc. (DXCM) fair value analysis

S&P 500 & Nasdaq · Updated 2026-09-07

DexCom, Inc. manufactures and distributes continuous glucose monitoring systems designed to help people with diabetes track their blood sugar levels in real time. The company operates globally, serving patients in multiple countries through its glucose monitoring technology and related products.

Forward Fair Value verdict

Undervalued

Based on TickrTrends' weekly Forward Fair Value model, DXCM is trading at more than a 25% discount to estimated fair value.

DXCM currently ranks #20 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Undervalued for 3 consecutive weekly runs.

Last price: $87.90
Sector: Healthcare
12-month range: $58.22–$90.14

Derived indicators

Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.

Quality grade: A
Momentum grade: A
Leverage: Moderate
Margin trend: Contracting
Revenue growth: Strong
RSI zone: Neutral
50/200-day trend: Uptrend
52-week position: The top quarter of its range

What our data shows for DXCM

Our model validated 12 trailing price-to-earnings windows for DXCM, built from quarterly earnings records.
Shares are trading in the upper third of their 12-month price range of $58.22–$90.14.
The 14-day relative strength index sits at a neutral 57.
4 of the last 12 weekly snapshots showed positive price momentum.

The exact numbers are one step away

The precise Forward Fair Value dollar figure for DXCM
Exact discount / premium to today's price
The normalized historical P/E behind the estimate, and how many quarters support it
Forward EPS input and fiscal-year basis
Screeners and rankings across the full S&P 500 and Nasdaq universes

See the exact fair value →

How Forward Fair Value works

TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.

Recent DXCM news

TickrTrends' derived news-sentiment signal for DXCM is currently mixed, computed from recent coverage.

Why Bellevue Sees Medtech Stocks Making a Comeback (finews.asia, 2026-09-04)
TickrTrends take: DexCom operates in the healthcare sector where medtech stocks are reportedly positioned for a comeback, which aligns with TickrTrends' current assessment that DXCM is undervalued. For a valuation-focused reader, the key consideration is whether broader medtech momentum will narrow the gap between DXCM's current price and its fundamental value. Monitoring sector rotation trends and investor appetite for healthcare technology will be important indicators of whether this undervalued designation proves prescient.
DexCom: Still A Cautious Buy Following Earnings (NASDAQ:DXCM) (seekingalpha.com, 2026-08-03)
TickrTrends take: DexCom operates in the Healthcare sector where continuous glucose monitoring technology represents a growing market segment. TickrTrends currently derives an Undervalued verdict for DXCM, suggesting the market price may not fully reflect the company's fundamentals. Investors focused on valuation metrics should monitor whether upcoming earnings results and revenue growth rates support or challenge this undervalued positioning in the competitive diabetes care market.

What people are saying

Follow the DXCM conversation: Stocktwits · Reddit · X

TickrTrends weekly updates

2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
2026-09-06 — # DXCM Weekly Indicator Summary TickrTrends' derived indicators for DXCM show a significant shift this week. The DCF cross-check band moved from an overvalued designation to none, indicating a change in the valuation assessment framework. The current valuation verdict remains undervalued for this Healthcare sector company.
2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.

Frequently asked questions

Is DXCM stock undervalued?

Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), DXCM is trading at more than a 25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.

What is DXCM's TickrTrends verdict?

DXCM's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.

How does DXCM compare to other Healthcare stocks?

DXCM ranks #20 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.

Is DXCM overbought or oversold?

DXCM's 14-day RSI is in neutral territory - neither overbought nor oversold.

All Healthcare fair-value coverage →

Head-to-head comparisons

DXCM vs AMPH · DXCM vs COO · DXCM vs HQY · DXCM vs ISRG · DXCM vs MNKD